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ABSTRACT Cefiderocol is a parenteral siderophore cephalosporin with a catechol-
containing 3= substituent. We evaluated its MICs against Gram-negative bacteria, us-
ing iron-depleted Mueller-Hinton broth. The panel comprised 305 isolates of Entero-
bacterales, 111 of Pseudomonas aeruginosa, and 99 of Acinetobacter baumannii, all
selected for carbapenem resistance and multidrug resistance to other agents. At 2
and 4 g/ml, cefiderocol inhibited 78.7 and 92.1%, respectively, of all Enterobactera-
les isolates tested, with rates of 80 to 100% for isolates with all modes of carbap-
enem resistance except NDM enzymes (41.0% inhibited at 2 g/ml and 72.1% at
4 g/ml) or combinations of extended-spectrum -lactamase (ESBL) and porin loss
(61.5% inhibited at 2 g/ml and 88.5% at 4 g/ml). Cefiderocol also inhibited 81.1
and 86.5% of all P. aeruginosa isolates at 2 and 4 g/ml, respectively, with rates of
80 to 100% for isolates with VIM, IMP, GES, or VEB -lactamases and slightly lower
rates for those with NDM (45.5% at 2 g/ml and 72.7% at 4 g/ml) and PER (66.7%
at 2 g/ml and 73.3% at 4 g/ml) enzymes; 63.3% of P. aeruginosa isolates were in-
hibited at the FDA’s 1-g/ml breakpoint. Lastly, cefiderocol at 2 and 4 g/ml inhib-
ited 80.8 and 88.9% of the A. baumannii isolates, respectively, with rates of 85%
for isolates with OXA-51-like, -23, -24, or -58 enzymes and 50% at 2 g/ml and 80%
at 4 g/ml for those with NDM carbapenemases. Dipicolinic acid and avibactam
weakly potentiated cefiderocol against Enterobacterales isolates with metallo--
lactamases (MBLs) and serine carbapenemase, respectively, indicating incomplete
-lactamase stability.
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Carbapenem-resistant Gram-negative bacteria have proliferated globally and are agrowing problem, prioritized by the WHO (1). Their resistance can be caused
by acquired carbapenemases or can arise through combinations of porin loss and
extended-spectrum or AmpC -lactamases (2). Carbapenemases are the greater prob-
lem insofar as many producers can transfer their -lactamase genes horizontally. Their
enzymes—which variously include KPC, OXA-48-like, and metallo (IMP, NDM, and VIM)
-lactamase (MBLs)—are biochemically diverse, complicating the design of stable
-lactams and inhibitors.
Many carbapenemase producers are resistant to multiple antibiotics besides
-lactams, including fluoroquinolones, aminoglycosides, and antifolates (30). Conse-
quently, clinicians have been forced to redeploy polymyxins, despite doubts about their
pharmacokinetics and dose optimization, along with concerns regarding efficacy and
renal toxicity (3).
New -lactamase inhibitor combinations are beginning to provide alternatives, with
trials or case series supporting superiority over colistin combinations (4–6). Ceftazidime-
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avibactam is active against most Enterobacterales isolates with KPC and OXA-48-like
enzymes, while meropenem-vaborbactam and imipenem-relebactam inhibit those with
KPC enzymes only (7, 8). However, none of these combinations are active against
Enterobacterales isolates with MBLs, nor against the vast majority of carbapenemase-
producing isolates of Pseudomonas aeruginosa and Acinetobacter baumannii (9, 10).
Cefiderocol is a novel parenteral siderophore cephalosporin approved in the United
State for the treatment for complicated urinary tract infections (cUTI), and in the
European Union (EU) for the treatment of infections due to aerobic Gram-negative
bacteria in adults with limited treatment options. It has a catechol moiety attached via
its 3-position side chain, allowing uptake into Gram-negative bacteria via the ferric iron
transporter system (11–13). We evaluated its activity against multidrug-resistant clinical
isolates of Gram-negative bacteria from the United Kingdom, prioritizing those with
carbapenem resistance (Table 1).
RESULTS
Overall MIC distributions. The isolate panel was deliberately loaded with highly
resistant organisms (Table 2), as reflected in the fact that no comparator agent was
active against 90% of isolates and only colistin achieved 80% activity across all
TABLE 1 Panel of isolates used in this study
Genus or species
No. of isolates with:








loss GES IMI SME VEB PER OXA-23 OXA-24/40 OXA-51 OXA-58
Klebsiella 20 17 5 20 22 6 7 5 102
E. coli 21 15 5 21 20 11 7 100
Enterobactera 10 8 4 9 9 8 5 3 5 61
Serratia 1 3 2 1 4 1 5 17
Citrobacter 3 7 1 3 3 17
Morganella 2 2
Providencia 3 1 4
Proteus 1 1
Hafnia alvei 1 1
P. aeruginosa 11 30 25 20 10 15 111
A. baumannii 20 41 9 19 10 99
Total 92 77 40 56 56 26 25 29 5 5 10 15 41 9 19 10 515
aIncludes 8 isolates of Klebsiella aerogenes (formerly Enterobacter aerogenes) and 1 isolate of Pluralibacter gergoviae (formerly Enterobacter gergoviae).
TABLE 2 Overall resistance rates among test panel isolates
Agent(s)
% of isolates at EUCAST or CLSI breakpoint shown in parentheses (g/ml)
Enterobacterales (n  305) P. aeruginosa (n  111) A. baumannii (n  99)
EUCAST R CLSI not S EUCAST R CLSI not S EUCAST R CLSI not S
Cefiderocol 21.3 (2) 7.9 (4)a 18.9 (2) 13.5 (4)a 19.2 (2)b 11.1 (4)a
Meropenem 58.4 (8) 93.8 (1) 85.9 (8) 92.8 (2) 98 (8) 99 (2)
Ceftazidime 87.2 (4) 97.2 (4) 99.1 (8) 99.1 (8) 95 (8)
Ceftazidime-avibactam 41.6 (8) 41.6 (8) 77.5 (8) 77.5 (8)
Cefepime 79 (4) 87.2 (2) 86.5 (8) 86.5 (8) 98 (8)
Ceftolozane-tazobactam 87.2 (2) 87.2 (2) 96.4 (4) 96.4 (4)
Aztreonam 71.8 (4) 72.1 (4) 53.2 (16) 66.7 (8)
Amikacin 29.5 (8) 17.7 (16) 69.4 (16) 69.4 (16) 55.6 (8) 55.6 (8)
Ciprofloxacin 62 (0.5) 68.5 (0.25) 89.2 (0.5) 89.2 (0.5) 93.9 (1) 93.9 (16)
Tigecycline 42 (0.5)c 7.9 (2)d 82 (2)d 30.3 (2)d
Colistin 16.4 (2) 16.4 (2)e 16.2 (2) 16.2 (2)e 11.1 (2) 11.1 (2)c
aProvisional CLSI breakpoint used before licensing: the FDA has since published values of S  2 g/ml for Enterobacterales (as for EUCAST) and S  1 g/ml for P.
aeruginosa. A total of 63.3% of the isolates were susceptible at the latter value.
bNo EUCAST breakpoint. The proportion susceptible at 2 g/ml is cited for comparability with other species.
cEUCAST breakpoint of 0.5 g/ml officially only for E. coli and C. koseri adopted for all species.
dFDA breakpoint, as there was no CLSI value.
eNo susceptible breakpoint for colistin, so intermediate breakpoint used.
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groups; tigecycline achieved activity versus 90% of Enterobacterales isolates based on
the FDA 2-g/ml breakpoint but only 42.0% based on the EUCAST 0.5-g/ml value,
which, strictly, is only applicable to Escherichia coli and Citrobacter koseri.
Among comparator -lactams, ceftazidime-avibactam was the most active combi-
nation against Enterobacterales, inhibiting 41.6% of isolates at its breakpoint of 8 g/ml
for ceftazidime plus 4 g/ml for avibactam, essentially comprising almost all those
without MBLs. Aztreonam was the most active -lactam against the P. aeruginosa panel,
inhibiting 46.8% of isolates—mostly MBL producers—at its 16-g/ml breakpoint. Re-
sistance to established -lactams, including ceftazidime-avibactam, was nearly univer-
sal in the A. baumannii panel.
Cefiderocol inhibited 78.7% of Enterobacterales isolates at 2 g/ml and 92.1% at
4 g/ml; corresponding proportions for the P. aeruginosa collection were 81.1 and
86.5%, respectively, although only 63.3% were inhibited at the FDA’s 1-g/ml break-
point. The proportions of the Acinetobacter collection inhibited at 2 and 4 g/ml were
80.8 and 88.9%, respectively; neither CLSI nor the FDA has breakpoints for this genus.
Enterobacterales. MICs of cefiderocol were widely scattered within enterobacterial
species and had no obvious association with species (Fig. 1). Accordingly, further
analysis was done with reference to resistance mechanism rather than species. At
2 g/ml, cefiderocol inhibited 80% of isolates in all Enterobacterales groups except
those with NDM carbapenemases (41% inhibited) or combinations of extended-
spectrum -lactamases (ESBLs) and porin loss (61.5% inhibited) (Table 3). At 4 g/ml,
cefiderocol inhibited 95% of isolates in all Enterobacterales groups, except for (i) those
with NDM MBLs (72.1% inhibited) and (ii) those with combinations of ESBL and
impermeability (88.5% inhibited).
Irrespective of species, the MIC distribution for Enterobacterales isolates with NDM
enzymes was extended and elevated compared with those for isolates with other MBLs.
This behavior was independent of aztreonam resistance, indicating that higher
cefiderocol values, where seen, were not contingent upon coresident ESBL or AmpC
enzymes (Table 4).
P. aeruginosa. At 2 g/ml, cefiderocol inhibited 81.1% of P. aeruginosa isolates
tested, with rates between 90.0 and 93.3% for all groups, except for those with IMP
(80.0%), PER (66.7%), and NDM (45.5%) -lactamases (Table 3). At 4 g/ml, cefiderocol
inhibited 86.5% of P. aeruginosa isolates tested, with rates between 90.0 and 100% for
all resistance mechanism groups, except for those with IMP (80.0%), PER (73.3%), or
NDM enzymes (72.7%). Cefiderocol MICs of 128 g/ml were recorded for two isolates:
one with an NDM carbapenemase and one with a VIM carbapenemase.
FIG 1 Cefiderocol MIC distribution, by species, for Enterobacterales isolates (n  305). An asterisk indi-
cates that the data for Enterobacter include 8 isolates of Klebsiella aerogenes (formerly Enterobacter
aerogenes) and 1 isolate of Pluralibacter gergoviae (formerly Enterobacter gergoviae).
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As with Enterobacterales, cefiderocol MICs for P. aeruginosa isolates with NDM
carbapenemases were elevated compared with those for isolates with other mecha-
nisms, although it should be cautioned that (i) the behavior seemed less marked and
(ii) only 11 P. aeruginosa isolates with NDM carbapenemases were tested—far fewer
than the 61 Enterobacterales isolates.
A. baumannii. At 2 g/ml, cefiderocol inhibited 80.8% of the test panel of A.
baumannii isolates, with rates of 85% for all groups, except for those with NDM
carbapenemases (50.0%); at 4 g/ml, it inhibited 88.9% (Table 2), with rates of 87%
for all groups, except for those with NDM carbapenemases (80.0%) (Table 3). Never-
TABLE 3 MIC distributions of cefiderocol by resistance mechanism and species group
Mechanism





<0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 >128 2 4
Enterobacterales
NDM 3 3 6 13 19 13 2 2 41.0 72.1
KPC 9 4 10 7 5 10 6 4 1 91.1 98.2
OXA-48 like 13 5 6 7 10 6 5 3 1 92.9 98.2
VIM 2 1 3 10 9 11 2 7 2 80.9 95.7
ESBL  porin loss 2 6 2 6 7 2 1 61.5 88.5
AmpC  porin loss 2 3 6 4 4 6 100 100
IMP 2 1 6 1 4 1 93.3 100
GES, IMI, or SME 3 3 3 3 2 5 100 100
Total 26 16 27 42 41 41 47 41 19 2 3 78.7 92.1
P. aeruginosa
VIM 1 2 10 4 6 4 1 1 1 93.3 93.3
IMP 5 4 7 3 1 3 2 80.0 80.0
GES 4 2 5 5 1 1 2 90.0 100
PER 1 2 2 3 2 1 2 2 66.7 73.3
NDM 2 3 3 1 1 1 45.5 72.7
VEB 4 3 2 1 90.0 90.0
Total 1 12 16 18 20 14 9 6 7 6 2 81.1 86.5
A. baumannii
OXA-23 2 11 11 5 3 3 1 1 1 3 85.4 87.8
NDM 3 7 6 1 1 2 50.0 80.0
OXA-51 5 7 5 1 1 94.7 94.7
OXA-58 2 3 4 1 90.0 90.0
OXA-24/40 1 3 2 2 1 88.9 100
Total 9 21 21 9 8 12 8 1 3 1 6 80.8 88.9
TABLE 4 Distributions of cefiderocol versus aztreonam MICs for Enterobacterales isolates
with NDM carbapenemasesa
Aztreonam MIC (g/ml)
No. of isolates with cefiderocol MIC (g/ml) of:
Total0.25 0.5 1 2 4 8 16 32
0.5 1 2 2 7 4 2 1 19
1 2 1 3
2 1 2 1 1 5
4 1 2 3
8 1 1
16 0
32 1 1 1 2 1 6
64 1 4 4 7 7 1 24
Total 3 3 6 13 19 13 2 2 61
an  61 isolates.
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theless, MICs of 64 g/ml were recorded for 7 of the 99 isolates, comprising two with
NDM carbapenemases, four with OXA-23, and one with OXA-58.
MIC distributions for A. baumannii with NDM or OXA-23 enzymes were elevated
compared with those for isolates with other mechanisms. A caveat to note: although
Table 3 indicates that 10% of A. baumannii isolates with OXA-58 carbapenemases were
resistant to cefiderocol at 128 g/ml, this represents only a single isolate, meaning that
significance is limited.
Cefiderocol combined with -lactamase inhibitors. Because cefiderocol MICs for
isolates with NDM carbapenemases were generally higher than those for isolates with
other carbapenemases, we sought to explore whether these isolates could inactivate
the compound. To do this, we redetermined MICs of cefiderocol together with dipic-
olinic acid (100 g/ml), as an inhibitor of MBLs, and avibactam (4 g/ml), as an inhibitor
of any coproduced serine -lactamases, and with a combination of both these inhib-
itors. A panel of 40 Enterobacterales isolates with NDM enzymes was used together with
small control groups representing other carbapenemases or mechanisms (Table 5).
Avibactam alone had predictably little effect on the MICs of cefiderocol for the
isolates with NDM enzymes: only 1/40 NDM-positive Enterobacterales isolates showed
a 2-fold reduction in cefiderocol MIC. Dipicolinic acid, in contrast, achieved 4- to
32-fold reductions in MIC for 25/40 blaNDM-positive isolates, with combination MICs
ranging from 0.03 to 16 g/ml and a mode of 1 g/ml, compared with 4 g/ml for
cefiderocol alone. There was a greater effect when both inhibitors were tested together
in combination with cefiderocol, with 4- to 64-fold MIC reductions for 36/40 blaNDM-
positive isolates. Using this triple combination, all 40 NDM-positive isolates were
inhibited by cefiderocol at 2 g/ml compared with 22.5% for cefiderocol alone.
The control groups were small, reducing the strength of conclusions for individual
enzyme types: nonetheless, MICs of cefiderocol for isolates with VIM enzymes generally
TABLE 5 MICs of cefiderocol for 64 Enterobacterales isolates determined with and without -lactamase inhibitors
lnhibitor and agent(s)a
MIC (g/ml)
<0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32
NDM (n  40)
Cefiderocol 5 4 13 12 4 2
 avibactam 2 3 6 12 10 5 2
 dipicolinic acid 1 3 2 5 11 7 8 2 1
 avibactam and dipicolinic acid 1 3 2 8 6 15 5
VIM (n  6)
Cefiderocol 1 2 3
 avibactam 1 1 3 1
 dipicolinic acid 2 2 2
 avibactam and dipicolinic acid 1 1 1 2 1
KPC (n  5)
Cefiderocol 2 2 1
 avibactam 1 4
 dipicolinic acid 3 1 1
 avibactam and dipicolinic acid 2 3
OXA-48 like (n  4)
Cefiderocol 1 1 2
 avibactam 1 1 1 1
 dipicolinic acid 1 1 1 1
 avibactam and dipicolinic acid 1 2 1
ESBL  porin loss or AmpC  porin loss (n  8)
Cefiderocol 1 1 4 2
 avibactam 1 3 1 2 1
 dipicolinic acid 1 2 1 2 1 1
 avibactam and dipicolinic acid 1 4 1 1 1
an indicates the number of isolates.
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showed 2- to 4-fold reductions when dipicolinic acid was added alone or together with
avibactam, whereas no reductions were seen with only avibactam added. Conversely,
the MICs of cefiderocol for isolates with KPC or OXA-like carbapenemases, or with
combinations of ESBL and porin loss, mostly were reduced by the addition of avibactam
alone or combined with dipicolinic acid, whereas dipicolinic acid alone had minimal
effect.
DISCUSSION
Cefiderocol is the first catechol -lactam to be licensed. It combines efficient entry
into Gram-negative bacteria with considerable -lactamase stability. These factors
support in vitro activity against otherwise extremely resistant Enterobacterales isolates
and nonfermenters, at least under iron-deficient conditions. Thus, as found here and by
others (12–14), cefiderocol inhibited the majority of carbapenem-resistant Gram-
negative bacteria, tested irrespective of species, at 2 or 4 g/m. This activity encom-
passed many MBL-producing isolates of Enterobacterales, P. aeruginosa, and A. bau-
mannii, as well as isolates of A. baumannii with OXA carbapenemases, whereas these
groups typically are unequivocally resistant to new -lactamase inhibitor combinations,
including ceftazidime-avibactam (as confirmed here), meropenem-vaborbactam, and
imipenem-relebactam (15–17).
These aspects are positive, but three interlinked areas of uncertainty remain: the
“correct” breakpoints, the activity against bacteria with NDM carbapenemases, and
the clinical efficacy against carbapenemase producers. The breakpoint issues have
been recently and well summarized by Simner and Patel (18). Succinctly, a provi-
sional CLSI value of susceptible (S)  4 g/ml and resistant (R)  4 g/ml was
adopted in development and has been retained as a reference point here; however,
EUCAST has subsequently advised breakpoints of S  2 g/ml and R  2 g/ml for
all species, and the FDA has adopted values of S  2 g/ml and R  4 g/ml for
Enterobacterales and S  1 g/ml and R  2 g/ml for P. aeruginosa, with the last
of these values predicated on a cUTI trial (19) where there was only a single P.
aeruginosa isolate with a MIC of 1 g/ml. It is not now clear whether CLSI will
retain their provisional values or adopt the lower FDA values; a decision is antici-
pated in 2021 (18).
These breakpoint issues become particularly pertinent for bacteria with NDM car-
bapenemases, as the MICs of cefiderocol for these mostly were higher than those for
isolates of the same species with other carbapenemases. In particular, cefiderocol MICs
were 4 g/ml for 17/61 (27.9%) of Enterobacterales isolates with NDM carbapen-
emases compared with 2/62 (3.2%) of those with VIM and IMP MBLs (P  0.001,
chi-square test). This behavior was unrelated to aztreonam resistance or suscepti-
bility, implying that the higher MICs reflected the NDM enzymes themselves and
not coproduced ESBLs or AmpC enzymes. To explore this aspect further and to
determine if NDM enzyme protected bacteria against cefiderocol, we undertook
combination tests with -lactamase inhibitors. The results supported the view that
cefiderocol is not completely -lactamase stable, as it was frequently, though
weakly, potentiated by dipicolinic acid against the isolates with NDM (particularly)
and VIM MBLs and by avibactam for isolates with KPC, OXA-48, ESBL, and AmpC
enzymes. Additional synergy for Enterobacterales isolates with NDM enzymes when
both dipicolinic acid and avibactam were added is surprising. It may be that
avibactam inhibits coresident class A or D -lactamases, but were this a significant
factor, one would expect the MICs of unprotected cefiderocol to be higher for aztreonam-
resistant, NDM-positive Enterobacterales isolates than for their aztreonam-susceptible coun-
terparts lacking ESBLs or AmpC enzymes, and this was not the case (Table 4).
The significance of this slight -lactamase lability is difficult to judge: imipenem
remains clinically useful against P. aeruginosa, unless OprD is lost, despite lability to the
organism’s chromosomal AmpC enzyme (20); on the other hand, breakpoints for
oxyimino cephalosporins against Enterobacterales have had to be lowered substantially
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because even modestly raised values have been associated with clinical failures when
ESBLs are present (21).
Relating these MIC observations to clinical data is presently difficult. Recent phase
III trials have shown cefiderocol to be effective and noninferior to imipenem-cilastatin
for the treatment of cUTIs and to meropenem in nosocomial pneumonia caused by
Gram-negative bacteria (19, 22). However, these trials mostly recruited patients with
broadly susceptible pathogens, and a further study, CREDIBLE-CR (23, 24), gave more
equivocal results. This compared cefiderocol with “best available therapy”— comprising
colistin or its combinations in 66% of cases—in multiple infection types involving
carbapenem-resistant Gram-negative bacteria. Overall, cefiderocol achieved compara-
ble clinical and microbiologic outcomes to its comparators, but disturbingly, there was
a significant excess of deaths in the cefiderocol arm, many involving infections with
Acinetobacter spp. Formal publication and analysis of these data are awaited, and the
issue of outcomes relative to enzyme type as well as species and MIC will be of vital
importance. More positively, several case reports have appeared describing the suc-
cessful use of cefiderocol as compassionate therapy in infections involving difficult
extremely resistant pathogens (25–27).
Ultimately, accumulating clinical experience will determine cefiderocol’s utility
against carbapenemase-producing Gram-negative bacteria. Given the drug’s unusual
mode of uptake, this utility may depend on the degree of iron starvation that applies
at a particular infection site. What can fairly be said at this stage is that its MICs for many
isolates that are resistant to other new agents are sufficiently low to permit a degree
of guarded optimism.
MATERIALS AND METHODS
Bacteria. The test isolates (Table 1) comprised (i) 305 isolates of Enterobacterales, selected to
represent diverse carbapenemase producers and isolates with carbapenem resistance via combinations
of porin loss with AmpC or ESBL activity; (ii) 111 isolates of P. aeruginosa, selected to represent producers
of MBLs and GES carbapenemases, along with isolates that produced VEB or PER ESBLs and were
carbapenem resistant via OprD loss; and (iii) 99 isolates of A. baumannii with NDM MBLs or various OXA
carbapenemases.
In selecting isolates from Public Health England’s Antimicrobial Resistance and Healthcare Associated
Infections (PHE-AMRHAI) Reference Unit collections for inclusion, we favored organisms with phenotypes
for other -lactams (cefiderocol had not previously been tested), typical of their mechanisms but
including susceptible and resistant representatives for antibiotics that divide isolates within groups. Thus,
for example, groups with metallo--lactamases were selected to include both aztreonam-resistant
organisms (inferred also to have ESBLs or AmpC enzymes) and those that were aztreonam susceptible
(inferred to lack ESBLs or AmpC enzymes). We ensured that the isolates were from diverse hospitals and
excluded multiple isolates from single patients. Almost all of the organisms were submitted by hospital
laboratories in the United Kingdom between 2008 and 2018 for investigation of unusual resistance
phenotypes and/or susceptibility testing for therapeutic guidance. Exceptions were 3 isolates referred to
the PHE-AMRHAI Reference Unit from hospitals in the Republic of Ireland and 11 isolates of Pseudomonas
aeruginosa with PER ESBLs, which were collected in Turkey in the early 1990s (28).
Carbapenemases and VEB and PER enzymes were identified by PCR of their encoding genes or by
whole-genome sequencing (WGS). Carbapenem resistance due to porin loss combined with ESBL or
AmpC activity was inferred from previous susceptibility results and the absence of carbapenemase, as
confirmed by PCR or WGS. Species identification was by matrix-assisted laser desorption ionization–time
of flight (MALDI-TOF) mass spectroscopy.
MIC testing. MICs were determined using preprepared broth microdilution plates (IHMA, Inc.,
Schaumburg, IL) with antibiotic dilutions in cation-adjusted Mueller-Hinton broth (CAMHB) (29). Iron-
depleted CAMHB (ID-CAMHB) was used for cefiderocol only and was prepared by IHMA, by treating
CAMHB with a cation-binding resin (Chelex; Bio-Rad), followed by removal of resin by filtration and
addition of Mg2, Ca2, and Zn2 ions at concentrations of 20 to 25, 10 to 12.5, and 0.5 to 1.0 g/ml,
respectively. The comparator antibiotics were meropenem, ceftazidime, ceftazidime-avibactam (4 g/
ml), cefepime, ceftolozane-tazobactam (4 g/ml), aztreonam, colistin, amikacin, ciprofloxacin, and tige-
cycline, all sourced by IHMA.
A subpanel of 64 Enterobacterales isolates was similarly tested on a second broth microdilution plate
that included cefiderocol alone, cefiderocol-avibactam (4 g/ml), cefiderocol-dipicolinic acid (100 g/ml),
and cefiderocol plus both avibactam (4 g/ml) and dipicolinic acid (100 g/ml). ID-CAMHB was used.
We reviewed results against published breakpoints: EUCAST has values of S  2 g/ml and R 
2 g/ml for Enterobacterales and P. aeruginosa; the FDA has values of S  2 g/ml and R  4 g/ml for
Enterobacterales and S  1 g/ml and R  2 g/ml for P. aeruginosa; CSLI still has values under review,
but previously, when cefiderocol was in trial, had investigational values of S  4 g/ml and R  8 g/ml.
MICs of comparator antibiotics were interpreted using EUCAST guidelines where available, the excep-
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tions being ceftazidime and cefepime for Acinetobacter spp., for which only CLSI breakpoints are
available.
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